epoetin alfa
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | RETACRIT | — | 2020-06-30 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | EPOGEN/PROCRIT | — | 1993-04-01 – 2011-06-24 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Abseamed | — | 2009-06-18 | europa.eu ↗ |
| Approved | EU (EMA) | NeoRecormon | — | 1997-07-16 | europa.eu ↗ |
| Approved | US (FDA) | EPOGEN/PROCRIT | — | 1989-06-01 | fda.gov ↗ |
Trials 319 · started per year
Also used as a comparator or background therapy in 148 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04073849 Comparator | Jul 2019 → Nov 2020 | — | Sports Medicine Research and Testing Laboratory | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT03992066 Background | May 2019 → May 2020 | anemia due to chronic disorder | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03683810 Background | Jan 2019 → Jan 2023 | anemia | Cyprus University of Technology | Unknown | No outcome recorded |
| Phase 1 | NCT03786289 Comparator | Dec 2018 → Jul 2019 | — | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02920372 Background | Nov 2016 → Jan 2017 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03572647 Comparator | Nov 2012 | chronic kidney disease | Azidus Brasil | Completed | No outcome recorded |
| Phase 1 | NCT01800305 Comparator | Sep 2012 → Oct 2014 | — | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01584921 Comparator | Mar 2012 → Aug 2013 | — | University of Copenhagen | Completed | No outcome recorded |
| Phase 1 | NCT01170078 Comparator | Jul 2010 → Jan 2011 | chronic renal failure syndrome | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00294203 Comparator | Feb 2006 → Dec 2008 | anemia | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT00005787 Background | Sep 1999 → Jan 2002 | lymphoma, neutropenia | Northwestern University | Terminated | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06903559 Comparator | Apr → Oct 2025 overdue | cardiovascular disorder, chronic renal failure syndrome, end stage renal failure, protein-energy malnutrition | Mansoura University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06917950 Comparator | Apr → Oct 2025 overdue | end stage renal failure, mixed anxiety and depressive disorder | Mansoura University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04013646 Comparator | May 2019 → Nov 2020 | stroke disorder | Bundang CHA Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02802592 Comparator | May 2015 → Jun 2016 | cardiac valvular defect | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01913340 Comparator | Sep 2013 → Jan 2016 | brain hypoxia - ischemia, perinatal asphyxia | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT00910234 Comparator | Aug 2009 → Jul 2011 | intracerebral hemorrhage, periventricular leukomalacia, pulmonary immaturity, retinopathy of prematurity | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT05265325 Comparator | May 2023 → Feb 2024 | anemia | Kind Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 2 | NCT04231292 Comparator | Mar → Jun 2020 | anemia | Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03950687 Comparator | Jun 2019 → Jun 2020 | chronic renal failure syndrome | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 2 | NCT03799627 Comparator | Jan 2019 → Jun 2020 | anemia, chronic kidney disease | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03715881 Comparator | Dec 2018 | non-arteritic anterior ischemic optic neuropathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03029247 Comparator | Jul 2017 → Jul 2020 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03315897 Comparator | Jul 2017 → Oct 2022 | bipolar disorder, cognitive disorder, major depressive disorder | Lars Vedel Kessing | Completed | No outcome recorded |
| Phase 2 | NCT03140722 Comparator | May 2017 → Mar 2018 | anemia, chronic kidney disease | Akebia Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02586402 Comparator | Oct 2015 → Aug 2016 | anemia, chronic renal failure syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02335593 Background | Dec 2014 → Nov 2015 | end stage renal failure | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02251041 Comparator | Sep 2014 → Feb 2019 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT02148367 Comparator | Sep 2014 → Jun 2016 | traumatic brain injury | Uniformed Services University of the Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT02064426 Comparator | Mar 2014 → Oct 2016 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01975818 Comparator | Oct 2013 → Oct 2015 | anemia, chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01596855 Comparator | Sep 2011 → Jan 2013 | aregenerative anemia | Kyntra Bio | Completed | No outcome recorded |
| Phase 2 | NCT01102218 Comparator | Aug 2010 → Jan 2012 | end stage renal failure | Fresenius Medical Care North America | Terminated | No outcome recorded |
| Phase 2 | NCT01147666 Comparator | May 2010 → Oct 2012 | anemia, end stage renal failure | Kyntra Bio | Completed | No outcome recorded |
| Phase 2 | NCT01467115 Background | Mar 2010 → Jun 2014 | head and neck cancer | Drexel University College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00924781 Background | Jun 2009 → Apr 2010 | anemia, chronic kidney disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01015352 Comparator | Feb 2009 → Mar 2014 | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Completed | No outcome recorded |
| Phase 2 | NCT00680043 Comparator | Jun 2008 → Aug 2009 | anemia, chronic renal failure syndrome | Affymax | Completed | No outcome recorded |
| Phase 2 | NCT00624312 Comparator | Feb 2008 → Jan 2010 | cancer | University of Louisville | Withdrawn | No outcome recorded |
| Phase 2 | NCT00528593 Comparator | Nov 2007 → Oct 2009 | HIV infectious disease, sensory peripheral neuropathy | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT00622934 Comparator | Jul 2007 → May 2008 | — | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00449488 Comparator | Jan 2007 → Oct 2009 | myocardial infarction | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT00367991 Comparator | Nov 2006 → Mar 2008 | myocardial infarction | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00355095 Comparator | Aug 2006 → Feb 2011 | optic neuritis | Institute of Application-oriented Research and Clinical Trials GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00334737 Comparator | Jun 2006 → Dec 2013 | — | University of New Mexico | Completed | No outcome recorded |
| Phase 2 | NCT03102021 Comparator | Mar 2006 → Jun 2013 | acute kidney injury | North Texas Veterans Healthcare System | Completed | No outcome recorded |
| Phase 2 | NCT00378352 Comparator | Sep 2005 → Jul 2009 | ST-elevation myocardial infarction | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 2 | NCT00210626 Comparator | Aug 2005 → Jun 2008 | anemia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
| Phase 2 | NCT00520468 Background | Jun 2004 → Jun 2009 | myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00049348 Background | Oct 2003 → Oct 2005 | malignant pancreatic neoplasm | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00744445 Comparator | Oct 1993 → Aug 1998 | anemia, chronic renal failure syndrome | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07636486 Comparator | Jun 2026 → Jun 2028 expected | engraftment syndrome, hematopoietic and lymphoid cell neoplasm | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05476042 Comparator | Aug → Nov 2022 | conjunctival vascular disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03821168 Comparator | Mar → Apr 2019 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT02002039 Comparator | Jun 2012 → Jun 2016 | perinatal asphyxia | Sheri Kashmir Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00313716 Comparator | Apr 2006 → Mar 2013 | anemia, traumatic brain injury | Claudia Sue Robertson | Completed | No outcome recorded |
| Phase 2/3 | NCT00604630 Comparator | Jan 2003 → Jun 2008 | middle cerebral artery infarction | Max-Planck-Institute of Experimental Medicine | Completed | No outcome recorded |
| Phase 360 trials | ||||||
| Phase 3 | NCT07422480 Comparator | May 2026 → Apr 2029 expected | anemia, myelodysplastic syndrome | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT07296146 Comparator | Dec 2025 → Mar 2026 overdue | anemia, chronic kidney disease | Badr University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06352138 Comparator | Jul 2025 → Mar 2027 expected | anemia due to chronic disorder | Megalabs | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06520826 Comparator | Nov 2024 → Jun 2026 overdue | anemia due to chronic disorder | USRC Kidney Research | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06364150 Background | Jul 2024 → May 2025 overdue | acute myocardial infarction | Seoul National Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05949684 Comparator | Oct 2023 → Mar 2028 expected | myelodysplastic syndrome | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06720025 Comparator | Sep 2023 → Jun 2024 | anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05669079 Background | Aug 2023 → Aug 2026 overdue | — | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05907499 Background | Jul 2023 → Jul 2026 overdue | — | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05211167 Comparator | Jul 2021 → Jun 2023 | chronic renal failure syndrome | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT04588311 Comparator | Nov 2020 → Dec 2026 expected | traumatic brain injury | Australian and New Zealand Intensive Care Research Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT03682536 Comparator | Jan 2019 → Mar 2023 overdue | myelodysplastic syndrome | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03400033 Comparator | Sep 2018 → Jun 2020 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03308448 Comparator | Jan 2018 → Aug 2022 | optic nerve disorder | Iran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03110341 Comparator | Apr 2017 → Dec 2018 | cerebral palsy, intracerebral hemorrhage, periventricular leukomalacia | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT02811263 Comparator | Jan 2017 → Oct 2021 | perinatal asphyxia | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT02879305 Comparator | Sep 2016 → Nov 2020 | allergic bronchopulmonary aspergillosis, anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03408639 Comparator | Jun 2016 → Jul 2017 | aregenerative anemia | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT02652806 Comparator | Dec 2015 → Jan 2017 | anemia | Kyntra Bio | Completed | No outcome recorded |
| Phase 3 | NCT02273726 Comparator | Jan 2015 → Sep 2018 | — | Kyntra Bio | Completed | No outcome recorded |
| Phase 3 | NCT02278341 Comparator | Nov 2014 → Jun 2017 | anemia, end stage renal failure | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 3 | NCT02174731 Comparator | Jul 2014 → Sep 2018 | anemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02052310 Comparator | Feb 2014 → Sep 2018 | anemia | Kyntra Bio | Completed | No outcome recorded |
| Phase 3 | NCT01693029 Comparator | Sep 2012 → May 2014 | anemia, chronic kidney disease | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT02390102 Comparator | Jun 2012 → Jun 2015 | anemia, aortic valve stenosis | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Completed | No outcome recorded |
| Phase 3 | NCT01473407 Comparator | Jan 2012 → Feb 2014 | chronic renal failure syndrome | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01473420 Comparator | Jan 2012 → Feb 2014 | chronic renal failure syndrome | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00987454 Comparator | May 2010 → May 2015 | traumatic brain injury | Australian and New Zealand Intensive Care Research Centre | Completed | No outcome recorded |
| Phase 3 | NCT00827021 Comparator | Jul 2009 → Jul 2014 | chronic renal failure syndrome | Giovanni FM Strippoli, MD | Completed | No outcome recorded |
| Phase 3 | NCT00773331 Comparator | Jul 2009 → Dec 2010 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00717821 Comparator | Aug 2008 → Jul 2011 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00560404 Comparator | Apr 2008 → Dec 2010 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00605293 Comparator | Jan 2008 → Jan 2010 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00546481 Comparator | Nov 2007 → Dec 2009 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00597584 Comparator | Oct 2007 → Jul 2009 | anemia, chronic renal failure syndrome | Affymax | Completed | No outcome recorded |
| Phase 3 | NCT00701714 Comparator | Sep 2007 → Jul 2009 | anemia, chronic kidney disease | Sandoz | Terminated | No outcome recorded |
| Phase 3 | NCT00597753 Comparator | Sep 2007 → Jul 2009 | anemia, chronic renal failure syndrome | Affymax | Completed | No outcome recorded |
| Phase 3 | NCT00492427 Comparator | Jun 2007 → Jan 2008 | — | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00442793 Comparator | May 2007 → May 2010 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00454246 Comparator | Apr 2007 → Feb 2008 | anemia | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT00422513 Comparator | Mar → Dec 2007 | anemia | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT00442416 Comparator | Feb 2007 → Jan 2008 | anemia | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT00390832 Comparator | Dec 2006 → Mar 2009 | myocardial infarction | German Heart Center Munich | Completed | No outcome recorded |
| Phase 3 | NCT00319150 Comparator | Oct 2006 → Feb 2009 | chronic kidney disease | Queen's University | Terminated | No outcome recorded |
| Phase 3 | NCT00262379 Comparator | Dec 2005 → Jun 2009 | chronic hepatitis C virus infection | University Hospital, Angers | Completed | No outcome recorded |
| Phase 3 | NCT00146224 Comparator | Sep 2005 → Jan 2007 | — | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00711958 Comparator | Nov 2004 → Jul 2005 | anemia | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT00090753 Comparator | Oct 2004 → Dec 2009 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00081484 Comparator | Jun 2004 → Mar 2006 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00077623 Comparator | Mar 2004 → Sep 2005 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00077610 Comparator | Feb 2004 → Aug 2005 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00236951 Comparator | Feb 2003 → Oct 2005 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00111137 Comparator | Feb → Nov 2003 | cancer | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00236938 Background | Jul 2002 → Sep 2004 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00248339 Comparator | May 2002 → Jul 2005 | hepatitis C virus infection | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 3 | NCT00038064 Comparator | Jan 2002 → Oct 2003 | anemia, neoplasm | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00236964 Comparator | Feb 2001 → May 2002 | anemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00014222 Comparator | Dec 2000 → Feb 2014 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00527137 Comparator | Aug 2000 → Nov 2004 | end stage renal failure | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00321919 Comparator | Jul 2000 → Oct 2004 | anemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT07162090 Comparator | Sep 2025 → Sep 2026 expected | anemia due to chronic disorder, muscular atrophy | Tianjin Medical University General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07045155 Comparator | Aug 2025 → Dec 2027 expected | anemia due to chronic disorder, end stage renal failure | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04134026 Comparator | Oct 2022 → Oct 2023 | anemia | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT05683782 Comparator | Oct 2022 → Jul 2023 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04655027 Comparator | Feb → Oct 2021 | anemia due to chronic disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT04959578 Comparator | Feb 2018 → Jan 2019 | anemia due to chronic disorder | Rufaida Mazahir | Completed | No outcome recorded |
| Phase 4 | NCT03277183 Comparator | Nov 2017 → Jun 2019 | anemia, atherosclerosis, chronic kidney disease | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 4 | NCT02522975 Comparator | Aug 2015 → Jun 2019 | anemia | Shenyang Sunshine Pharmaceutical Co., LTD. | Terminated | No outcome recorded |
| Phase 4 | NCT02707757 Comparator | Jul 2015 → Dec 2016 | anemia | Imperial College Healthcare NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT03658876 Comparator | Jun 2015 → Dec 2016 | anemia, chronic renal failure syndrome | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT02876211 Background | Dec 2014 → Aug 2022 | anemia | Hospital Son Espases | Terminated | No outcome recorded |
| Phase 4 | NCT02049346 Comparator | Mar 2012 → Apr 2013 | anemia due to chronic disorder | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02817555 Comparator | Sep 2010 → May 2013 | anemia, chronic kidney disease | Andrea L Woodland | Completed | No outcome recorded |
| Phase 4 | NCT00773513 Comparator | Dec 2008 → Jul 2017 | anemia due to chronic disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00626574 Comparator | Jul 2007 → Feb 2009 | subarachnoid hemorrhage | University of South Florida | Terminated | No outcome recorded |
| Phase 4 | NCT00526448 Background | Jun 2007 → Feb 2010 | chronic hepatitis C virus infection | Hospital Carlos III, Madrid | Unknown | No outcome recorded |
| Phase 4 | NCT00470210 Background | May 2007 → Jun 2009 | HIV infectious disease, chronic hepatitis C virus infection | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00511901 Comparator | Nov 2005 → May 2008 | anemia | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
| Phase 4 | NCT00356486 Background | Oct 2005 → Mar 2009 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00476619 Comparator | Sep 2004 → Nov 2007 | acute tubulointerstitial nephritis | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00440063 Background | — | anemia | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT02984111 Comparator | Jan 2016 → Jan 2017 | myocardial ischemia | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT02496377 Background | Aug 2014 → Oct 2016 | blood group incompatibility, osteoarthritis, hip, osteoarthritis, knee | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT01902511 Comparator | Jul 2013 → Dec 2015 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01888003 Comparator | Apr 2013 → Jan 2015 | iron deficiency anemia | University of Alabama at Birmingham | Terminated | No outcome recorded |
| — | NCT01823029 Background | Nov 2012 → Jul 2013 | Crohn disease | Jinling Hospital, China | Completed | No outcome recorded |
| — | NCT01320449 Comparator | Aug 2011 → Jul 2012 | substance abuse | University of Aarhus | Completed | No outcome recorded |
| — | NCT00258440 Comparator | May 2003 → Sep 2008 | anemia, cancer of unknown primary site | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| — | NCT00577096 Comparator | Oct 2001 → Jun 2004 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| — | NCT00593801 Comparator | May 1998 → Jun 1999 | anemia | Charite University, Berlin, Germany | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-05-15 | Pfizer | Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA pfizer.com ↗ |
| 2017-05-25 | Pfizer | FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications pfizer.com ↗ |
| 2016-04-08 | Novartis Pharmaceuticals | Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication novartis.com ↗ |
Evidence & citations 66 cited values
Every value below carries the sentence it was read from. 506 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epoetin alfa | “BACKGROUND: EPREX®/ERYPO®/PROCRIT® (epoetin alfa, Janssen-Cilag GmbH) was the first available recombinant human erythropoietin (rHuEPO) and was universally reference product as...” PMID 36451454 ↗ Nov 2022213“This phase III study aimed to compare the efficacy and safety of CinnaPoietin® (epoetin beta, CinnaGen) with Eprex® (epoetin alfa, Janssen Cilag) in the treatment of anemia in...” PMID 30253403 ↗ Sep 2018 “rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.” NCT03457701 ↗ “administration of single preoperative high dose shot of epoetin alfa (rhEPO) in a young (age \< 65 years of age) population undergoing cardiac surgery” NCT02802592 ↗ “Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline.” NCT00924781 ↗ “HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia.” PMID 29084409 ↗ Oct 2017 “epoetin alfa if they were receiving hemodialysis or darbepoetin alfa if they were receiving peritoneal dialysis” PMID 34739194 ↗ Nov 2021 “Epoetin alfa (Binocrit, Sandoz, Poland) given intravenously when Hb \<120 g/L, dosed by a study subject weight:” NCT06670963 ↗ “Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)” NCT06520826 ↗ “PROCRIT (epoetin alfa, a glycoprotein that stimulates red blood cell production)” NCT00267007 ↗ “PROCRIT (Epoetin alfa) is a brand of recombinant human erythropoietin (rHuEPO).” NCT00337935 ↗ “Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection” NCT00869856 ↗ “Epoetin alfa may cause the body to make more red blood cells.” NCT00258440 ↗ “Epoetin alfa, a well established drug to treat renal anemia” NCT00322413 ↗ “Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®))” NCT00210626 ↗ “Recombinant human erythropoietin (rHuEPO, epoetin alfa)” NCT03683810 ↗ “subcutaneous Eporon versus Epoetin Alfa (Eprex)” NCT03521713 ↗ “Epoetin Alfa (Amgen)” NCT01473420 ↗ |
| Known as | Binocrit | “Epoetin alfa (Binocrit, Sandoz, Poland) given intravenously when Hb \<120 g/L, dosed by a study subject weight:” NCT06670963 ↗1“Binocrit” NCT04588311 ↗ |
| Known as | Brand name of Erythropoietin: Espogen (made by LG Life Science) | “Brand name of Erythropoietin: Espogen (made by LG Life Science)” NCT01193660 ↗ |
| Known as | darboepoetin | “Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose” NCT02390102 ↗ |
| Known as | Ebio | “domestic rHuEPO (trade name: Ebio).” NCT04910594 ↗ |
| Known as | Epiao | “Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week.” NCT01624038 ↗ |
| Known as | EPO | “This therapy will consist of hCG (3 once-daily IM doses at 10,000 IU per dose, one day apart, on days 1, 3 and 5 of study participation), followed by a one day washout period...” NCT00362414 ↗41“This work was conducted to evaluate the effect of early intervention with epoetin alfa (EPO) on transfusion requirements, hemoglobin level (Hb), quality of life (QOL) and to...” PMID 15953714 ↗ Jul 2005 “Erythropoietin (EPO) is approved by the FDA to treat anemia and has comprehensive preclinical data supporting its neuroprotective and neuroregenerative efficacy following...” NCT02226848 ↗ “The primary objective of this randomized, placebo-controlled study is to determine the effect of early administration of recombinant human Epo (rhEpo), on long-term...” NCT00313716 ↗ “Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment...” PMID 19834012 ↗ Oct 2009 “PURPOSE: An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for...” PMID 26858335 ↗ Feb 2016 “The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24...” NCT00413946 ↗ “Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting osteoclastic resorption.” NCT06513039 ↗ “The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing.” PMID 33504262 ↗ Apr 2021 “Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood.” NCT00149058 ↗ “Erythropoietin (EPO) is a cytokine originally identified for its role in erythropoiesis and more recently shown to be produced in the central nervous system.” NCT00945789 ↗ “Erythropoietin (Epo) is a cytokine with remarkable neuroprotective and neuroregenerative effects demonstrated in animal models of neonatal brain injury.” NCT02811263 ↗ “To determine the safety and pharmacokinetics of erythropoietin (Epo) given in conjunction with hypothermia for hypoxic-ischemic encephalopathy (HIE).” PMID 23008465 ↗ Sep 2012 “Erythropoietin (EPO), a multi-functional glycoprotein hormone, exhibits erythropoietic and non-erythropoietic anti-inflammatory properties.” PMID 39548414 ↗ Nov 2024 “Research in recent years suggest in both animal and human studies that erythropoietin (Epo) may have significant neuroprotective effects.” NCT00589953 ↗ “Erythropoietin (EPO) is a glycoprotein hormone produced predominantly by the kidney that regulates the synthesis of red blood cells.” NCT05683782 ↗ “Erythropoietin (EPO) is a kidney-produced erythropoietic hormone that has known immune-modulating effects, including Treg induction.” PMID 33721837 ↗ Mar 2021 “Erythropoietin (EPO) has been shown to be neurotrophic and neuroprotective in several animal models and some clinical studies.” NCT03914690 ↗ “Erythropoietin (Epo) is a hormone normally found in the body that may protect brain cells from damage due to lack of oxygen.” NCT00491413 ↗ “This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight.” NCT01203514 ↗ “Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) will be injected for a total of 4 days” NCT06364150 ↗ “associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).” NCT02496377 ↗ “Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3.” NCT01962571 ↗ “adding Erythropoietin (EPO) in granulocyte-colony stimulating factor (G-CSF)-mobilized stem cell therapy” PMID 29962032 ↗ Aug 2018 “receive either a single dose of EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.” NCT01364402 ↗ “recombinant human erythropoietin (EPO) treatment has desirable as well as undesirable effects” PMID 20383871 ↗ Jul 2010 “recombinant human erythropoietin (Epo) has been shown to exert neuroprotective action” NCT02076373 ↗ “Erythropoietin (EPO) is a hematopoietic hormone and has multiple biological effects.” NCT05360511 ↗ “2 agents are available in Canada, epoetin alfa (EPO) and darbepoetin alfa (DA).” PMID 28717516 ↗ Jun 2017 “Erythropoietin (EPO) enhances re-endothelialization and anti-apoptotic action.” PMID 20834185 ↗ Sep 2010 “Erythropoietin (EPO) is the most widely prescribed cytokine” NCT03277183 ↗ “human chorionic gonadotropin (hCG), then epoetin alfa (EPO)” NCT00938314 ↗ “erythropoietin (EPO) treatment in spinal shock” NCT00561067 ↗ “Erythropoietin (EPO) on neonatal hearts” PMID 22564802 ↗ May 2012 “recombinant human erythropoietin (EPO)” NCT00260052 ↗ “Recombinant human erythropoietin (EPO)” NCT07162090 ↗ “Erythropoietin (EPO) with xenograft” NCT06601400 ↗ “intravitreal erythropoietin (EPO)” PMID 31401683 ↗ Aug 2019 “Erythropoetin (EPO)” NCT01384565 ↗ “erythropoetin (EPO)” NCT00298597 ↗ |
| Known as | EPO Hexal | “HX575, EPO Hexal” NCT00869856 ↗1“HX575, EPO HEXAL” NCT00701714 ↗ |
| Known as | EPO-beta | “high doses of epoetin beta (EPO-beta)” PMID 20642691 ↗ Jul 2010 |
| Known as | EPO-α | “On the basis of promising animal data, this study evaluated any potential benefits of erythropoietin-alfa (EPO-α) given intra-arterially at the time of reperfusion of renal...” PMID 22745272 ↗ Jun 2012 |
| Known as | Epoetin | “In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in patients on prevalent hemodialysis switching from a prior...” PMID 35918106 ↗ Aug 202212“Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron...” NCT06903559 ↗ “Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron...” NCT06917950 ↗ “Erythropoietin (Epoetin 4000 IU)” NCT07296146 ↗ |
| Known as | Epoetin Alfa (Amgen) | “This study assessed the comparability of the pharmacokinetics (PK) of epoetin following intravenous administration of Hospira Epoetin and Epogen/Epoetin Alfa (Amgen) in...” NCT01170078 ↗ |
| Known as | Epoetin alfa DT | “To determine whether Epoetin alfa manufactured by a roller bottle technology (Epoetin alfa RB) and Epoetin alfa manufactured by a deep tank process (Epoetin alfa DT) have a...” NCT00156962 ↗ |
| Known as | Epoetin alfa HEXAL | “Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3.” NCT01962571 ↗ |
| Known as | epoetin alfa or beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00081484 ↗ |
| Known as | Epoetin alfa RB | “To determine whether Epoetin alfa manufactured by a roller bottle technology (Epoetin alfa RB) and Epoetin alfa manufactured by a deep tank process (Epoetin alfa DT) have a...” NCT00156962 ↗ |
| Known as | epoetin alfa-epbx | “Low dose epoetin alfa-epbx recombinant (400 units/kg) subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk.” NCT05617833 ↗2“epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®)” PMID 30196301 ↗ Sep 2018 “Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa.” PMID 32734207 ↗ Aug 2019 |
| Known as | Epoetin alfa/beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02064426 ↗ |
| Known as | Epoetin alpha | “40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.” NCT03339596 ↗13“Patients were assigned to 12 weekly injections of subcutaneous epoetin alpha or placebo, targeting Hgb levels between 120 and 140 g/L.” PMID 17312332 ↗ Feb 2007 “Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 U/kg).” PMID 22098110 ↗ Nov 2011 “associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).” NCT02496377 ↗ “Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)” NCT00267007 ↗ “Epoetin alpha” NCT00513240 ↗ |
| Known as | Epoetin alpha or beta (Epoetin group) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02049346 ↗ |
| Known as | Epoetin beta | “We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times...” PMID 17950856 ↗ Oct 200745“Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.” NCT01975818 ↗ “30 000 IU Neorecormon â (epoetin beta) s.c.” NCT00145652 ↗ “Erythropoietin (Epoetin-beta, NeoRecormon®)” NCT01584921 ↗ “Erythropoietin (Epoetin beta)” NCT01889056 ↗ “Drug: Epoetin beta” NCT02876211 ↗ |
| Known as | Epoetin Hospira | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01628120 ↗ |
| Known as | Epoetin Omega | “Epoetin Omega, that differs from Epoetin alfa in the sugar moiety of the molecule” NCT00322413 ↗ |
| Known as | Epoetin Zeta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03598582 ↗ |
| Known as | epoetin-α | “HX575 was approved in the European Union in August 2007 as the first-ever biosimilar epoetin-α product.” PMID 22732334 ↗ Jul 2012 |
| Known as | epoetin-β | “either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗5“either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗ “azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.” PMID 27229713 ↗ May 2016 “With Epoetin β Support (450 IU/kg/Week)” NCT00356486 ↗ |
| Known as | epoetinum | “Drug: epoetinum” NCT00676234 ↗ |
| Known as | EPOGEN | “Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)” NCT06520826 ↗ |
| Known as | epoietinum-alpha | “The brand name is EPREX® which is epoietinum-alpha in sterile buffered solution for i.v. or s.c. injection.” NCT00676234 ↗ |
| Known as | EPORON | “EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.” NCT02580006 ↗ |
| Known as | EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU) | “EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU)” NCT02580006 ↗ |
| Known as | Epoétine beta | “Study Treatment: Neorecormon® (Epoétine beta) under cutaneous injection” NCT00396435 ↗ |
| Known as | eprax | “Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).” NCT04469777 ↗ |
| Known as | EPREX | “A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects...” NCT00211133 ↗12“The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.” NCT00002022 ↗ “EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.” NCT02580006 ↗ “subcutaneous Eporon versus Epoetin Alfa (Eprex)” NCT03521713 ↗ “50 UI/kg of Epoetin alpha (Eprex)” NCT01695759 ↗ “Erythropoetin (rHuEPO, EPREX®)” NCT00478517 ↗ “Eprex” NCT04588311 ↗ |
| Known as | Eritromax | “50 UI/kg of Epoetin alpha (Eritromax)” NCT01695759 ↗ |
| Known as | Erypo | “BACKGROUND: EPREX®/ERYPO®/PROCRIT® (epoetin alfa, Janssen-Cilag GmbH) was the first available recombinant human erythropoietin (rHuEPO) and was universally reference product as...” PMID 36451454 ↗ Nov 20223“Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 U/kg).” PMID 22098110 ↗ Nov 2011 |
| Known as | Erythropoetin | “Erythropoetin (Neorecormon) and ATRA” NCT00437450 ↗7“Erythropoetin (EPO)” NCT01384565 ↗ |
| Known as | Erythropoiesis-Stimulating Agent (ESA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03214627 ↗ |
| Known as | Erythropoietin | “This is a prospective, randomized multicenter phase III clinical trial designed to evaluate the safety and activity of comparison between Erythropoietin and Erythropoietin...” NCT00804050 ↗110“Erythropoietin (EPO) is approved by the FDA to treat anemia and has comprehensive preclinical data supporting its neuroprotective and neuroregenerative efficacy following...” NCT02226848 ↗ “Erythropoietin has antiapoptotic, antiexcitatory, and anti-inflammatory properties to prevent neuronal cell death in animal models, and improves neurodevelopmental outcomes in...” PMID 23102686 ↗ Oct 2012 “treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and...” NCT00310232 ↗ “The purpose of this research study was to determine if the activity of erythropoietin (r-HuEPO) is time dependent when given to chronic renal failure patients at three...” NCT00744445 ↗ “This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants.” NCT03919500 ↗ “The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.” NCT00002022 ↗ “Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) will be injected for a total of 4 days” NCT06364150 ↗ “adding Erythropoietin (EPO) in granulocyte-colony stimulating factor (G-CSF)-mobilized stem cell therapy” PMID 29962032 ↗ Aug 2018 “administration of erythropoietin (EPO) with intravenous iron supplementation” PMID 39022429 ↗ Jun 2024 “30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation” NCT00362414 ↗ “Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold” NCT05671250 ↗ “Erythropoietin (EPO) is a candidate neuroprotective drug.” PMID 37094997 ↗ Apr 2023 “4000IU once daily for three days of erythropoietin” NCT01239706 ↗ “intravenous erythropoietin administration” NCT00476619 ↗ |
| Known as | Erythropoietin beta | “Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy” NCT00875004 ↗ |
| Known as | erythropoietin-alfa | “On the basis of promising animal data, this study evaluated any potential benefits of erythropoietin-alfa (EPO-α) given intra-arterially at the time of reperfusion of renal...” PMID 22745272 ↗ Jun 20127“EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.” NCT02580006 ↗ “Biological: Erythropoietin alfa” NCT07025681 ↗ |
| Known as | Erythropoiétine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00180999 ↗ |
| Known as | HRE | “Previous studies at our Hospital have shown that high dose Human Recombinant Erythropoietin (HRE)effectively spares transfusions even when administered two days before surgery.” NCT01265680 ↗ |
| Known as | HrEPO | “Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial” NCT00945789 ↗ |
| Known as | Human Erythropoiesis Injection (CHO cell) | “Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT05211167 ↗ |
| Known as | human recombinant erythropoietin | “Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial” NCT00945789 ↗ |
| Known as | HX575 | “Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24...” NCT00666835 ↗6“Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.” NCT01576341 ↗ |
| Known as | HX575 epoetin alfa | “HX575 epoetin alfa” NCT00632125 ↗ |
| Known as | Neocormon | “Epoetin Beta (Neocormon®)” NCT00559195 ↗ |
| Known as | NeoRecormon | “Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on...” NCT04965961 ↗15“Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy” NCT00875004 ↗ “A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy” NCT02761642 ↗ “A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors” NCT02554942 ↗ “30 000 IU Neorecormon â (epoetin beta) s.c.” NCT00145652 ↗ “Erythropoietin (Epoetin-beta, NeoRecormon®)” NCT01584921 ↗ “Erythropoetin (Neorecormon) and ATRA” NCT00437450 ↗ “epoetin beta [NeoRecormon]” NCT00321919 ↗ “epoetin beta [NeoRecormon]” NCT00437723 ↗ “epoetin beta [NeoRecormon]” NCT00377481 ↗ “epoetin beta [NeoRecormon]” NCT00440063 ↗ “epoetin beta [NeoRecormon]” NCT00413101 ↗ “Neorecormon” NCT02707757 ↗ |
| Known as | PROCRIT | “This was an open-label (doctors and patients knew which drug was being administered), non-randomized (patients were assigned to treatment), multi-center pilot study with the...” NCT00388336 ↗39“The primary objective of this study is to compare the change in hemoglobin (Hb) from study start to the end of the study between the every 2 week and the every 4 week dosing...” NCT00212875 ↗ “The purpose of this study is to evaluate the effectiveness and safety of less frequent dosing of PROCRIT (Epoetin alfa) in patients with anemia due to Chronic Kidney Disease...” NCT00307814 ↗ “The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown...” NCT00228995 ↗ “The purpose of this study is to evaluate the effectiveness of PROCRIT (Epoetin alfa) 80,000 Units given once weekly or 80,000 Units given once every two weeks in anemic...” NCT00446602 ↗ “BACKGROUND: EPREX®/ERYPO®/PROCRIT® (epoetin alfa, Janssen-Cilag GmbH) was the first available recombinant human erythropoietin (rHuEPO) and was universally reference product as...” PMID 36451454 ↗ Nov 2022 “The primary objective of this study is to describe how four different dosing regimens of PROCRIT (epoetin alfa) are utilized in patients with anemia due to non-dialysis chronic...” NCT00641589 ↗ “Epoetin Alfa (Procrit) is a manufactured form of a naturally occurring hormone that is given as an injection by a medical professional to stimulate the bone marrow's production...” NCT00337441 ↗ “Comparative Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days” NCT00210756 ↗ “Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy” NCT00255749 ↗ “Patients will receive injections of PROCRIT (Epoetin alfa) 60,000 Units (U) once weekly (QW) under the skin for up to 12 weeks (Initiation Phase)” NCT00338416 ↗ “The patients will receive subcutaneous (under the skin) injections of Epoetin alfa (PROCRIT) at one of the following dosing regimens:” NCT00210834 ↗ “PROCRIT® (epoetin alfa) is an analogue of erythropoetin, a hormone secreted by kidneys known to stimulate red blood cell production.” NCT00261677 ↗ “The starting dose (Baseline/Study Day 1) of PROCRIT (Epoetin alfa) for all eligible subjects was 40,000 U given subcutaneously QW.” NCT00317902 ↗ “Subjects will be randomly assigned in a 1:1 ratio to receive either Epoetin alfa (PROCRIT®) or matching placebo for sixteen weeks.” NCT00240734 ↗ “treatment with PROCRIT® will help decrease any problems with thinking or short-term memory that chemotherapy may cause.” NCT00246597 ↗ “The starting dose of PROCRIT (Epoetin alfa) was administered subcutaneously (sc) as 40,000 Units (U) once weekly (qw).” NCT00524407 ↗ “80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks” NCT00386152 ↗ “A Pilot Trial of Extended Interval Dosing of Epoetin Alfa (Procrit®) for the Treatment of Anemia in Oncology Patients” NCT00258440 ↗ “The FDA has approved Procrit® (epoetin alfa) to treat anemia in people with non-myeloid (bone marrow) malignancies.” NCT00481624 ↗ “Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation” NCT00425126 ↗ “perisurgical regimen of epoetin alfa (PROCRIT®) versus the standard of care for blood conservation” NCT00211146 ↗ “Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.” NCT00210743 ↗ “PROCRIT (epoetin alfa, a glycoprotein that stimulates red blood cell production)” NCT00267007 ↗ “PROCRIT (Epoetin alfa) is a brand of recombinant human erythropoietin (rHuEPO).” NCT00337935 ↗ “PROCRIT (Epoetin alfa) is a hormone that stimulates red blood cells production.” NCT00401869 ↗ “receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo” NCT00210795 ↗ “Patients will receive weekly doses of PROCRIT® (Epoetin alfa).” NCT00211120 ↗ “Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®))” NCT00210626 ↗ “epoetin alfa (PROCRIT; 40,000 Units (U) SC weekly)” NCT00315484 ↗ “PROCRIT� (Epoetin Alfa)” NCT00236405 ↗ “Epoetin-alpha (Procrit)” NCT00248339 ↗ “PROCRIT (Epoetin alfa)” NCT00338299 ↗ “PROCRIT (Epoetin alfa)” NCT00495378 ↗ “PROCRIT (Epoetin alfa)” NCT00210600 ↗ “Epoetin Alfa (PROCRIT)” NCT00210587 ↗ “Procrit (epoetin alfa)” NCT00254436 ↗ |
| Known as | PROCRIT | “The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown...” NCT00228995 ↗1“receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo” NCT00210795 ↗ |
| Known as | r-HuEPO | “Before treatment initiation, subjects were randomized to subsequently receive growth factors, recombinant human erythropoietin (rHuEPO) and/or granulocyte colony-stimulating...” PMID 21876446 ↗ Nov 201125“An open-label, randomized, non-inferiority study of darbepoetin alpha (DA) and recombinant human erythropoietin(rHuEpo) for the treatment of anemia in children with chronic...” NCT04959578 ↗ “The efficacy of recombinant human erythropoietin (rHuEPO) in sparing red blood cell (RBC) transfusions in children with hemolytic uremic syndrome related to Shiga...” PMID 35166922 ↗ Feb 2022 “Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer...” NCT02767765 ↗ “either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗ “Since the release of the recombinant human erythropoietin (rhuEPO) at the beginning of the 90s, transfusions are less needed to treat anemia in chronic kidney disease patients.” NCT03401710 ↗ “ECAS survey showed that recombinant human erythropoietin (rHuEPO) was the main treatment for cancer anemia, but the treatment rate was low (17.4%)” NCT04910594 ↗ “comparing the efficacy of darbepoetin alfa with that of recombinant human erythropoietin (rHuEpo) in pediatric subjects with CKD.” PMID 16724235 ↗ May 2006 “Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression” NCT00220675 ↗ “patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy” NCT00120679 ↗ “rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT04231292 ↗ “rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT03950687 ↗ “with recombinant human erythropoietin (rhu-EPO) in myelodysplastic syndrome (MDS).” PMID 22936658 ↗ Aug 2012 “recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.” NCT00121030 ↗ “Recombinant human erythropoietin (rHuEPO, epoetin alfa)” NCT03683810 ↗ “recombinant human erythropoietin (rHuEPO)” PMID 23927461 ↗ Oct 2013 “Erythropoetin (rHuEPO, EPREX®)” NCT00478517 ↗ “Drug: rHuEPO” NCT00491868 ↗ |
| Known as | Recombinant erythropoietin injection (CHO cells) | “Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1” NCT03786289 ↗ |
| Known as | recombinant human Epo | “The primary objective of this randomized, placebo-controlled study is to determine the effect of early administration of recombinant human Epo (rhEpo), on long-term...” NCT00313716 ↗ |
| Known as | recombinant human erythropoietin | “compare the time to hematopoietic response (hemoglobin correction to 12 g/dL or a greater than or equal to 2 g/dL increase from baseline) for subjects randomized to receive...” NCT00111137 ↗44“Before treatment initiation, subjects were randomized to subsequently receive growth factors, recombinant human erythropoietin (rHuEPO) and/or granulocyte colony-stimulating...” PMID 21876446 ↗ Nov 2011 “The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia...” NCT00364455 ↗ “This randomized trial assessed the effect of recombinant human erythropoietin (EPO) vs preoperative autologous donation (PAD) on postoperative vigor and handgrip strength in...” PMID 17400086 ↗ Apr 2007 “Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment...” PMID 19834012 ↗ Oct 2009 “either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24, (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times per week...” NCT04965961 ↗ “Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously” NCT04954989 ↗ “roxadustat versus recombinant human erythropoietin (rHuEPO) on gastrointestinal iron absorption in patients with anemia of CKD (stage 4/5).” PMID 38280066 ↗ Jan 2024 “Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT05211167 ↗ “Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.” NCT06796660 ↗ “Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week” NCT05053893 ↗ “who have been receiving recombinant human erythropoietin (rHuEPO) treatment for at least 4 weeks” NCT07045155 ↗ “the use of recombinant human erythropoietin (EPO) has also been proposed in cardiac surgery” NCT04141631 ↗ “One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day” PMID 35279078 ↗ Mar 2022 “intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)” PMID 20199815 ↗ Mar 2010 “Recombinant human erythropoietin (rHuEPO, epoetin alfa)” NCT03683810 ↗ “Recombinant human erythropoietin injection (CHO cells)” NCT03786289 ↗ “recombinant human erythropoietin (rHuEPO)” PMID 23927461 ↗ Oct 2013 |
| Known as | recombinant human erythropoietin alfa | “HX575 recombinant human erythropoietin alfa” NCT00701714 ↗ |
| Known as | Recombinant Human Erythropoietin Beta | “Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer...” NCT02767765 ↗ |
| Known as | Recormon | “receive either a single dose of EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.” NCT01364402 ↗ |
| Known as | rEpo | “High-dose recombinant human erythropoietin (rEpo) has first been administered in clinical trials for neuroprotection in very preterm neonates at high risk of brain injury and...” PMID 22776958 ↗ Jul 20121“In animal studies, recombinant Epo (rEpo) administration, even up to six hours after oxygen deprivation, reduced subsequent brain injury by 50% to 70%.” NCT00491413 ↗ |
| Known as | RetacritTM | “epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®)” PMID 30196301 ↗ Sep 2018 |
| Known as | rhEPO | “This study evaluated the efficacy of combination therapy using allogeneic umbilical cord blood (UCB), a relatively safe therapeutic cell source, and recombinant human...” PMID 41456040 ↗ Dec 20257“The primary objective of this randomized, placebo-controlled study is to determine the effect of early administration of recombinant human Epo (rhEpo), on long-term...” NCT00313716 ↗ “Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300...” NCT01392612 ↗ “The objective of this study was to evaluate the protective effect of repeated low-dose recombinant human erythropoietin (rhEPO) in preterm infants with IVH.” PMID 33959935 ↗ May 2021 “The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients.” NCT03835507 ↗ “This study aimed to determine whether recombinant human EPO (rhEPO) could protect against NEC in very preterm infants.” PMID 32771013 ↗ Aug 2020 “intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)” PMID 20199815 ↗ Mar 2010 “recombinant human erythropoietin (rhEpo)” NCT00910234 ↗ |
| Known as | SEBOR | “Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week” NCT05053893 ↗ |
| Action | Activate | “Its function is to stimulate the production of red blood cells in the bone marrow.” NCT00337935 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Erythropoietin” NCT00002255 ↗ |
| Route | Subcutaneous | “erythropoietin administered subcutaneously” NCT00002073 ↗ |